Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vMCO-I in Advanced Retinitis Pigmentosa
NCT04919473Phase 2Completed
- Sponsor
- Nanoscope Therapeutics
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonpiretigene isteparvovec in retinitis pigmentosa (RP) (2 arms), sponsored by Nanoscope Therapeutics. Primary endpoint: Safety and tolerability of escalating doses of vMCO-I at 16 weeks. Started Oct 2019; status: completed.
02
Drugs
sonpiretigene isteparvovec
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04919473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919473.